Cablivi Approved for Pediatric Acquired Thrombotic Thrombocytopenic Purpura The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

The @fda.gov has expanded the approval of Cablivi® to include treatment of pediatric patients 12 years and older with #aTTP, in combination with plasma exchange and immunosuppressive therapy. From @medicalprofref.bsky.social.

https://bit.ly/4aTlSbu

#TTPawareness #iTTP #thrombosis